Abcam, ab267175, Human TRIM14 knockout A549 cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
TRIM14 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 4 and 2 bp deletion in exon 4 and 40 bp deletion in exon 4. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 10 bp deletion in exon 4 and 2 bp deletion in exon 4 and 40 bp deletion in exon 4,
Disease:Carcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TRIM14, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
TRIM14 also known as Tripartite Motif Containing 14 is a protein encoded by the TRIM14 gene. It has a molecular mass of approximately 53 kDa. The protein is part of the TRIM family characterized by a tripartite motif which includes a RING domain B-box type 1 and a coiled-coil region. TRIM14 is expressed in various tissues with higher levels observed in immune-related organs such as the spleen and lymph nodes.
Biological function summary
TRIM14 plays a role in innate immune response by modulating signaling pathways. It does not have E3 ubiquitin ligase activity like other TRIM family members but interacts with proteins in antiviral defenses. TRIM14 associates with the mitochondria contributing to the formation of complexes with proteins like MAVS which are involved in the antiviral response to RNA viruses.
Pathways
TRIM14 is integral to the regulation of innate immune signaling pathways. It participates in the RIG-I-like receptor signaling pathway essential for detecting viral RNA. TRIM14 does this through interaction with MAVS leading to the activation of downstream signaling proteins including NF-kB and IRF3. These proteins result in the production of type I interferons and pro-inflammatory cytokines.
TRIM14 is linked to immune-related conditions and viral infections. Variations in TRIM14 expression have been associated with hepatitis B virus infection where the protein's interaction with MAVS influences viral persistence and clearance. Additionally TRIM14 expression alterations relate to autoimmune disorders such as systemic lupus erythematosus where it may affect MAVS related pathways contributing to abnormal immune activation.